Vericel (VCEL) | Financial Analysis & Statements
Vericel Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
92.9M
Gross Profit
73.1M
78.70%
Operating Income
22.4M
24.12%
Net Income
23.2M
25.01%
EPS (Diluted)
$0.45
Balance Sheet Metrics
Total Assets
488.0M
Total Liabilities
133.3M
Shareholders Equity
354.6M
Debt to Equity
0.38
Cash Flow Metrics
Operating Cash Flow
10.9M
Free Cash Flow
12.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Vericel Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 276.3M | 237.2M | 197.5M | 164.4M | 156.2M |
| Cost of Goods Sold | 70.7M | 65.1M | 61.9M | 54.6M | 50.2M |
| Gross Profit | 205.6M | 172.1M | 135.6M | 109.8M | 106.0M |
| Gross Margin % | 74.4% | 72.6% | 68.6% | 66.8% | 67.9% |
| Operating Expenses | |||||
| Research & Development | 27.6M | 24.8M | 21.0M | 19.9M | 16.3M |
| Selling, General & Administrative | 167.0M | 142.8M | 121.0M | 106.9M | 97.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 194.6M | 167.6M | 142.0M | 126.8M | 113.9M |
| Operating Income | 11.0M | 4.5M | -6.5M | -17.1M | -7.9M |
| Operating Margin % | 4.0% | 1.9% | -3.3% | -10.4% | -5.0% |
| Non-Operating Items | |||||
| Interest Income | 7.0M | 6.4M | 4.6M | 1.3M | 224.0K |
| Interest Expense | 630.0K | 614.0K | 600.0K | 366.0K | 4.0K |
| Other Non-Operating Income | -44.0K | 195.0K | 64.0K | 95.0K | 52.0K |
| Pre-tax Income | 17.4M | 10.5M | -2.4M | -16.0M | -7.6M |
| Income Tax | 859.0K | 148.0K | 814.0K | 721.0K | -111.0K |
| Effective Tax Rate % | 4.9% | 1.4% | 0.0% | 0.0% | 0.0% |
| Net Income | 16.5M | 10.4M | -3.2M | -16.7M | -7.5M |
| Net Margin % | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% |
| Key Metrics | |||||
| EBITDA | 29.6M | 16.6M | 2.9M | -11.6M | -4.6M |
| EPS (Basic) | - | $0.21 | $-0.07 | $-0.35 | $-0.16 |
| EPS (Diluted) | - | $0.20 | $-0.07 | $-0.35 | $-0.16 |
| Basic Shares Outstanding | - | 48848000 | 47590000 | 47130000 | 46472000 |
| Diluted Shares Outstanding | - | 48848000 | 47590000 | 47130000 | 46472000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Vericel Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 100.1M | 74.5M | 69.1M | 51.1M | 68.3M |
| Short-term Investments | 37.4M | 41.7M | 40.5M | 68.5M | 35.1M |
| Accounts Receivable | 84.6M | 61.4M | 58.4M | 46.5M | 37.4M |
| Inventory | 17.6M | 17.4M | 13.1M | 16.0M | 13.4M |
| Other Current Assets | 7.7M | 7.3M | 6.9M | 4.8M | 4.2M |
| Total Current Assets | 247.4M | 212.8M | 205.6M | 186.9M | 158.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 64.8M | 70.1M | 73.5M | 41.6M | 45.8M |
| Goodwill | 5.6M | 6.2M | 6.9M | 7.5M | 0 |
| Intangible Assets | 5.6M | 6.2M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 341.0K | 556.0K | 771.0K | 1.3M | 528.0K |
| Total Non-Current Assets | 240.5M | 219.9M | 148.0M | 86.1M | 85.2M |
| Total Assets | 488.0M | 432.7M | 353.7M | 273.0M | 243.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.8M | 23.8M | 22.3M | 16.9M | 9.0M |
| Short-term Debt | 14.1M | 9.3M | 6.2M | 4.3M | 3.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | 116.0K | - | 41.0K | - |
| Total Current Liabilities | 49.1M | 50.3M | 45.7M | 37.5M | 26.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 82.3M | 89.6M | 81.9M | 43.3M | 47.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.9M | 876.0K | 100.0K | - | - |
| Total Non-Current Liabilities | 84.2M | 90.5M | 82.0M | 43.3M | 47.2M |
| Total Liabilities | 133.3M | 140.8M | 127.7M | 80.7M | 73.2M |
| Equity | |||||
| Common Stock | 730.7M | 684.8M | 629.2M | 593.2M | 553.9M |
| Retained Earnings | -376.3M | -392.8M | -403.2M | -400.0M | -383.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 354.6M | 292.0M | 226.0M | 192.3M | 170.5M |
| Key Metrics | |||||
| Total Debt | 96.4M | 98.8M | 88.0M | 47.6M | 50.2M |
| Working Capital | 198.3M | 162.5M | 159.9M | 149.4M | 132.4M |
Balance Sheet Composition
Vericel Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 16.5M | 10.4M | -3.2M | -16.7M | -7.5M |
| Depreciation & Amortization | 11.5M | 5.5M | 4.6M | 4.0M | 3.0M |
| Stock-Based Compensation | 38.8M | 36.5M | 32.3M | 37.2M | 34.3M |
| Working Capital Changes | -23.5M | -301.0K | -5.0M | -13.4M | -8.9M |
| Operating Cash Flow | 48.9M | 59.0M | 35.1M | 15.4M | 25.3M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | -7.9M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -72.4M | -68.2M | -55.2M | -69.6M | -60.0M |
| Investment Sales | 55.6M | 53.2M | 79.6M | 40.9M | 64.4M |
| Investing Cash Flow | -16.8M | -15.1M | 24.4M | -28.6M | -3.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 7.1M | 19.1M | 3.6M | 1.0M | 9.2M |
| Free Cash Flow | 24.7M | -5.8M | 7.8M | 10.1M | 21.1M |
| Net Change in Cash | 39.2M | 63.0M | 63.1M | -12.1M | 31.0M |
Cash Flow Trend
Vericel Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
106.36
Forward P/E
42.28
Price to Book
4.86
Price to Sales
6.27
PEG Ratio
7.09
Profitability Ratios
Profit Margin
5.98%
Operating Margin
24.12%
Return on Equity
5.11%
Return on Assets
1.50%
Financial Health
Current Ratio
5.03
Debt to Equity
27.32
Beta
1.21
Per Share Data
EPS (TTM)
$0.32
Book Value per Share
$7.01
Revenue per Share
$5.49
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VCEL | 1.8B | 106.36 | 4.86 | 5.11% | 5.98% | 27.32 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






